PARIS, September 3, 2018 / PRNewswire / – LG Chem, the chemistry division of LG Group, has signed an exclusive distribution partnership for France and Belgium with Laboderm – subsidiary of Novomed Group specialized in dermatology and aesthetic medicine – for the distribution of its YVOIRE range, innovative generation of injectable fillers based on cross-linked hyaluronic acid (HA) of non-animal origin.
The YVOIRE range revolutionizes the offer of fillers . Its exclusive “HICE” technology ( H igh C oncentration E qualized ) by a high molecular weight for a more lasting effect and greater elasticity, and on the other by a very low concentration of cross-linking agent BDDE ( Butyl Diglycidyl Ether ), guaranteeing more security. In total, its composition results in homogeneous products, easy to inject (fluidity and regularity) and more resistant to enzymatic degradation.
The range is available in three product categories (“Classic”, “Volume”, “Contour”) with or without lidocaine (for more comfort), offering practitioners wide possibilities of personalized interventions according to the patients.
Comfortable and ergonomic, the YVOIRE syringe is the result of research carried out in collaboration with renowned clinicians. They are offered in syringes pre-filled with ergonomics rewarded by the Grand Prix Design “ Korea Commodity ” in 2012.
YVOIRE is a safe product, easy to inject, with strong volumizing power in the duration. It has already conquered the world with five million syringes sold in more than 25 countries since its launch. France will be the new flagship country in the Korean chemist’s expansion strategy.
For Sophie Gomes, Managing Director of Laboderm: “ This exclusive partnership with LG Chem on the YVOIRE range is a major step forward in Laboderm’s strategy. Our goal: to extend our presence to the new specialties of the future, foremost among which is aesthetic medicine, which is attracting ever more general practitioners and responding to a growing demand from patients. It is by being distinguished by innovative products, while constantly reaffirming our commitment to a more effective and safer medicine (Editor’s note: the Novomed group is historically specialized in single-use medical devices aimed at fighting nosocomial diseases) , that Laboderm will always better meet the requirements of doctors performing dermatological or aesthetic procedures.
“Innovating for better quality medicine” is the motto of our Group, this is our commitment to all professionals and Health Institutions. »
For Ji Woong Kim, Commercial Director Europe of LG Chem:« YVOIRE is the filling product leader in Asia. We are convinced that there is considerable potential in France thanks to the alliance we are building with Laboderm. Their professionalism should allow us to be among the French leaders in aesthetic medicine. »
About Novomed Group and Laboderm
Founded in 1993, Novomed Group specializes in the design, manufacture and distribution of single-use medical devices that have become products essential in the fight against nosocomial infections, both in town and in hospital.
The Group, already a French leader with gynecologists and dermatologists through Gyneas and Laboderm , has become the leader in distribution to general practitioners and physiotherapists with the acquisition in 2017 of NM Medical and Kinessonne . Driven by a strong entrepreneurial dynamic since its creation, the group is geared towards innovation and guided by an approach of permanent upgrading. Novomed is thus developing other brands in synergy with the group’s historic activities: the complete range of dermo-cosmetic treatments Moraz , the line of cosmetic-repairing textiles Arnitex or the products of comfort for seniors, Novo’life .
About LG CHEM
A globally recognized player in the pharmaceutical industry, and an integral part of the Chemistry division of the holding company LG Corp, LG Chem has recorded a significant increase in recent years. his activity. LG Chem invests more than 20% of its revenues in innovation and development. The continuous evolution of its factories with the most modern technologies ensures production in accordance with standards established by the FDA, the EMEA and the WHO. For over 25 years, LG Chem has acquired recognized skills in the production of hyaluronic acid using state-of-the-art patented techniques that have already proven themselves in ophtamology and rheumatology.
+33 1 30 18 24 85